Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey

Journal of Infection and Chemotherapy

Volumn 18, Issue 1, 2012, Pages 41-46

  Sayan, Murat ^a   Kilic, Selcuk ^b   Uyanik, Muhammet Hamidullah ^c  

^a KOCAELI UNIVERSITY   (Turkey)

^b Refik Saydam National Public Health Agency   (Turkey)

^c ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Biovar; Brucella; Microbial sensitivity test; Rifampicin

Indexed keywords

RIFAMPICIN;

AGGLUTINATION TEST; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BIOTYPE; BRUCELLA MELITENSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURKEY (REPUBLIC);

EID: 84863479605     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0281-7     Document Type: Article

References (35)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006;6:91-9. (Pubitemid 43138907)
2. Food and Agriculture Organization of the United Nations, World Organisation for Animal Health, and World Health Organization (2006) Brucellosis in human and animals. WHO/CDS/EPR/2006.7. World Health Organization, Geneva
3. Foster G, Osterman BS, Godfroid J, Jacques I, Cloeckaert A. Brucella ceti sp. nov., and Brucella pinnipedialis sp. nov. for Brucella strains with cetaceans and seals as their preferred hosts. Int J Syst Evol Microbiol. 2007;57:2688-93. (Pubitemid 350187441)
4. Scholz HC, Hubalek Z, Vergnaud GI, Tomaso H, Al-Dahouk S, Melzer F. Brucella microti sp. nov. isolated from the common vole Microtus arvalis. Int J Syst Evol Microbiol. 2008;58: 375-82. (Pubitemid 351298409)
5. Scholz HC, Nöckler K, Göllner C, Bahn P, Vergnaud G, Tomaso H, et al. Brucella inopinata sp. nov. isolated from a breast implant infection. Int J Syst Evol Microbiol. 2010;60:801-8.
6. Del Vecchio VG, Kapatral V, Redkar RJ, Patra G, Mujer C, Los T, et al. The genome sequence of the facultative intracellular pathogen Brucella melitensis. Proc Natl Acad Sci USA. 2002;99: 443-8. (Pubitemid 34060380)
7. Yuce A, Cavus SA. Brucellosis in Turkey. Klimik Derg. 2006;19:87-97.
8. Yumuk Z, Dundar V. The effect of long-term ethanol feeding on efficacy of doxycycline plus rifampicin in the treatment of experimental brucellosis caused by Brucella melitensis in rats. J Chemother. 2005;17:509-13. (Pubitemid 41695598)
9. Colmenero JD, Gallardo FLC, Agundez JAG, Sedeno J, Betinez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994;38:2798-802. (Pubitemid 24374439)
10. Joint FAO/WHO expert committee on brucellosis. Sixth report. WHO Tech Rep Ser 1986;740:1-132.
11. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. Characterization of rpoB mutations in rifampicin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol. 2002;40:4435-8. (Pubitemid 35434927)
12. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104:901-12. (Pubitemid 32289282)
13. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents. 2004;23:405-7. (Pubitemid 38481556)
14. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother. 1999;43:1298-3000.
15. Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R. Genetic bases of the rifampicin resistance phenotype in Brucella spp. J Clin Microbiol. 2004;42:5439-43. (Pubitemid 39664317)
16. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis. 1991;13:523-4.
17. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents. 2005;26:101-5. (Pubitemid 41021960)
18. Gur D, Kocagoz S, Akova M, Unal S. Comparison of E-test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother. 1999;43:2337. (Pubitemid 29421232)
19. Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing. CLSI document 26:M100-S16. CLSI, Wayne, PA
20. Alton GG, Jones LM, Angus RD, Verger JM (1988) Techniques for the brucellosis laboratory. Institut National de la Recherche Agronomique (INRA), Paris, pp 34-61.
21. Simsek H, Erdenlig S, Oral B, Tulek N. Typing-biotyping of Brucella isolates of human origin and their epidemiologic evaluation. Klimik. 2004;17:103-6.
22. Kose S, Kilic S, Ozbel Y. Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey. J Basic Microbiol. 2005;45:323-7. (Pubitemid 41129324)
23. Ayaslioglu E, Kilic S, Aydin K, Kilic D, Kaygusuz S, Agalar C. Antimicrobial susceptibility of Brucella melitensis isolated from blood samples. Turk J Med Sci. 2008;38:257-62. (Pubitemid 351872825)
24. Kilic S, Dizbay M, Cabadak H. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis. J Chemother. 2008;20:33-7. (Pubitemid 351428659)
25. Sayan M, Yumuk Z, Bilenoglu O, Erdenlig S, Willke A. Genotyping of B. melitensis by rpoB gene analysis and re-evaluation of conventional serotyping method. Jpn J Infect Dis. 2009;62:160-3.
26. Refai M. Incidence and control of brucellosis in the Near East region. Vet Microbiol. 2002;90:81-110. (Pubitemid 35279871)
27. Erdenlig S, Iyisan AS, Baklan EA, Aksoy HY. Biovar distribution of Brucella isolates from livestock in Turkey, 1999 to 2006. In: 15th International congress of Mediterranean Federation for Health and Production of Ruminants, 15-19 May, 2007, Kusadasi-Turkey.
28. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob. 2006;5:1-4.
29. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis. 2003;35:337-8. (Pubitemid 36889331)
30. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E-test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol. 2005;43:140-3. (Pubitemid 40096291)
31. Rubinstein ER, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991;35:1925-7.
32. Martin TI, Sanchez GE, Martinez IM, Fresnadillo MJ, Sanchez GJE, Rodriguez GJA, et al. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother. 1999;43:194-5. (Pubitemid 29069228)
33. Sayan M, Yumuk Z, Dundar D, Bilenoglu O, Erdenlig S, Yasar E, et al. Rifampicin resistance phenotyping of B. melitensis by rpoB gene analysis in clinical isolates melitensis. J Chemother. 2008;20:431-5.
34. Esel D, Sumerkan B, Ayangil D, Telli M. Comparison of agar dilution method and E-test in the determination of antibiotic susceptibility of Brucella melitensis strains. Ankem Derg. 2004;18:196-9.
35. Oguz AV, Eroglu C, Guneri S, Yapar N, Oztop A, Sanic A, et al. RpoB gene mutations in rifampicin-resistant Mycobacterium tuberculosis strains isolated in the Aegean region of Turkey. J Chemother. 2004;16:442-5. (Pubitemid 39491070)